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CHAPTER 1: INTRODUCTION
Microbiota
The human body is home to around 3.9x1013 bacterial cells [1]. They are present in
several tissues like: gastrointestinal, urogenital, oral, nasal, and skin [2]. These microorganisms are collectively known as the microbiota. Much research has been directed at
understanding the role that these communities play in our health. In 2008 advances in
molecular biology and genome sequencing facilitated the implementation of the Human
Microbiome Project (HMP) [2, 3] by the National Institutes of Health (NIH). This was established not long after the Human Genome Project, but was not as widely known at the
time. However, the HMP has proven to have as powerful impact on our understanding of
many diseases. A growing number of research studies have focused on the microbiota
of the gut, in particular, since it has been correlated with chronic diseases such as type
2 diabetes, Chron’s disease, and obesity [4]. It is also a popular field of study since the
microbiota can be manipulated through different models using diet modification [5], fecal transplant [6], and even antibodies [7]. The gut microbiota is not unique to humans.
Bacterial communities are also found in other mammalian species like mice [8]. This
makes them easier to study since mice can act as a surrogate for studying in vivo interactions between host and microbiota.
Bacteroidetes, Firmicutes, and Proteobacteria are the most abundant phyla in our
gut [9], yet no two individuals share the same microbiota [2]. The exact composition
changes through our lifetime in both diversity and structure. It can also be affected by
antibiotic therapy, overseas traveling, and temporary illness [10]. This constant change
in the microbiota can many times go unnoticed and can have an influence on our health.
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We know that gut bacteria can play a beneficial role by increasing levels of shortchain fatty acids (SCFA) and preventing food allergies [11]. They are also capable of protecting against pathogens [12] and toxins [13] as well as maintaining the integrity of the
intestinal epithelial barrier [14]. However, they can also be detrimental to our health. The
gut microbiota can influence gastrointestinal disorders, colon cancer, hypertension, and
even asthma [9]. Some associated conditions like obesity or colitis have also been associated with the western lifestyle [15]. This makes us question whether the rise in certain diseases is due to an impaired or dysbiotic flora. If true, we have to wonder if there
are ways to stabilize the microbiota and what that would look like for each individual.
LPS + LBP
Lipopolysaccharides (LPS) provide structure and protection to the outer membrane
of almost all Gram-negative bacteria, especially those that are pathogenic such as Escherichia coli, Salmonella enterica, Neisseria meningitidis, Pseudomonas aeruginosa, and
Helicobacter pylori [16]. They consist of a hydrophobic domain known as lipid A endotoxin, a non-repeating oligosaccharide, and a distal polysaccharide, or O-antigen [17].
LPS that enters the mammalian bloodstream can cause many negative health effects.
Cells in the intestinal lining known as enterocytes can internalize Gram-negative bacteria through phagocytosis mediated by toll-like receptor 4 (TLR4) [18]. Lipoproteins like
chylomicrons become associated with a lipopolysaccharide binding protein (LBP) and
are responsible for inactivating the LPS from the dead bacteria and transporting it to
target tissues [19].
LBP is a 58 kDa glycoprotein [20] synthesized in the liver [21] that forms a complex
with LPS which can bind to CD14 receptors in macrophages or neutrophils and trigger

3
an inflammatory response involving interleukin-1 (IL-1) and IL-6 cytokines [22]. Elevated
serum LBP levels have been associated with heavy drinking [23], metabolic syndrome,
and obesity [24]. Levels tend to be higher in males and increase with age [25]. We know
that lifestyle factors can contribute to higher LBP levels, but LBP resulting from endotoxemia can also play a role in obesity and insulin resistance [26]. This means there is
more to obesity than an excess of food intake and that the microbiota can also play an
important role.
Bifidobacteria
The Bifidobacterium genus consists of Gram-positive, non-motile, non-spore-forming, rod-shaped, and often branched anaerobic bacteria. They belong to the Actinobacteria phylum. These bacteria are associated with animal habitats and have been isolated
from feces, sewage, human vagina, dental caries, and honey bee intestine [27]. They
cannot grow below 20˚C or above 46.5˚C and prefer a pH close to 6.5. In humans, bifidobacteria are most abundant at birth, likely due to the fermentation of maternal milk
[28]. While populations normally decrease with age, they can still be boosted through
consumption of certain foods [5, 29].
Commercially, we can find these bacteria added to food products like yogurt which
always propose some kind of health benefit. There does seem to be some protective
effect against enterocolitis [13, 30]. Studies have also shown a negative correlation between bifidobacteria abundance and abdominal pain in healthy adults [10]. Models have
shown that they can help reduce inflammation [31]. Still, there is another study suggesting that some bifidobacteria species may be associated with obesity [32].
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Lactobacillus
Lactobacillus bacteria are Gram-positive, non-spore-forming, fermentative, microaerophilic, chemo-organotrophic, and can occur as rods or coccobacilli [27]. They
belong to the Firmicutes phylum and are known for their ability to convert sugars into
lactic acid, which can function as a preservative in foods. Lactobacilli grow best at a
temperature of 30˚C to 40˚C. They are commonly incorporated as viable microorganisms in many foods and supplements. The list of lactobacilli used commercially is extensive and many have shown health benefits in mammals [33]. Despite this, there have
been other strains that have been known to cause infections. The most common
species that are associated with diseases are L. casei, L. rhamnosus, and L. plantarum
[34].
VSL#3
Probiotics consist of live microorganisms, like those usually found in yogurt, that
may have beneficial health effects. Most claim to provide some form of digestive or
gastrointestinal relief. Few probiotics have had the same success as VSL#3. This particular probiotic is a well studied mixture containing high concentrations of freeze-dried
bacteria (Bifidobacterium longum, Bifidobacterium breve, Bifidobacterium infantis, Lactobacillus acidophilus, Lactobacillus plantarum, Lactobacillus paracasei, Lactobacillus bulgaricus, and Streptococcus thermophilus) [35]. The label states it contains over 225 billion bacteria that are 10 times as potent than the average probiotic [36]. This product is
sold in capsule as well as powder form. Many studies have demonstrated positive effects in the dietary management of irritable bowel syndrome (IBS) [37, 38], ulcerative
colitis [39-41], and an ileal pouch [42].

5
Potato Resistant Starch
Potato starch is a commercially available polysaccharide extracted from the potato
root/vegetable. A serving of Bob’s Red Mill Unmodified Potato Starch, 1 tablespoon, has
40 calories and 10 g of total carbohydrates. It is mainly used as a thickener in soups
with similar cooking functionality to corn starch. Recently, it has grown in popularity
among consumers afflicted with gastrointestinal issues like IBS. This product is classified as a resistant starch (RS), “defined as that fraction of dietary starch, which escapes
digestion in the small intestine” [43]. It is also considered a prebiotic because its indigestible compounds can act as a substrate for the growth of healthy bacteria in the gut.
Amylopectin and amylose polymers are the main components of potato starch.
These starches get fermented by the gut microbiota which produce short chain fatty
acids (SCFA) that are primarily composed of acetic, propionic, and butyric acids [44].
This can lower the pH in the lumen and protect against the formation of cancerous tumors [45]. Resistant starches seem to provide a higher proportion of butyric acid than
other indigestible carbohydrates [44]. This is important because butyric acid can act as
a powerful anti-inflammatory agent for colonic cells by inhibiting IL-12 and up regulating
IL-10 [46]. It also keeps toxins out of the bloodstream by reducing intestinal permeability
[47].
Considering Supplements
Although supplements are regulated by the Food and Drug Administration, they do
not undergo the same approval process as medications. Supplements are assumed to
be safe until proven otherwise. The lack of clinical trials makes it difficult to assess the
effectiveness of one supplement against another. Consumers rely on labels and per-
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sonal experience. This is sometimes not enough to make informed decisions. For example, VSL#3 has been found to restructure the gut microbiota into a community that
protects against diseases like colitis [48]. Potato starch also changes the microbiota
into one that produces high levels of butyrate [49] which strengthen the intestinal wall
[47] and reduce inflammation [46]. Consumers report similar health benefits using either
VSL#3 or potato starch. These products are especially popular among groups suffering
with IBS. However, VSL#3, can be many times more expensive than potato starch. This
makes it unattainable to many. Therefore, there is a need to understand the differences
between supplements to justify a higher price point. Our study is the first to compare
the short-term effects of VSL#3 against potato starch in a healthy mouse model.
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CHAPTER 2: OBJECTIVES
1) Design a replicable, non-invasive, mouse model for testing supplements.
2) Test two commercially-available supplements associated with a beneficial microbiota and gastrointestinal relief: VSL#3 and potato starch.
3) Study the associated physiological changes in response to 15 days of dietary supplementation.
4) Compare the effectiveness of each diet in modifying the host microbiota.
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CHAPTER 3: METHODS
Animals
Twenty-four male C57BL/6 mice, 21 days old, were obtained from The Jackson Laboratory (Bar Harbor, ME) and used in this study following experimental protocol
(16-03-061) approved by The Institutional Animal Care and Use Committee (IACUC) at
Wayne State University (Detroit, MI). Sani-chips bedding was used instead of corn cob in
order to minimize consumption by the animals. Mice were randomly assigned to one of
6 small cages (n = 4, per cage) with free access to food and water. After 2 days of acclimation, the mice were placed in one of three treatment groups and were labelled as
shown in Figure 2. Briefly, three out of four mice in every cage were labelled using permanent markers (Sharpie, Oak Brook, IL) at the base of their tails in colors: red, green,
and blue. The first two cages (n = 8) were fed a control chow diet: PicoLab® Laboratory
Rodent Diet 5L0D (LabDiet, St. Louis, MO). The remaining 4 cages were divided into two
test groups: potato starch and VSL#3. The 10% potato starch supplemented diet (Bob’s
Red Mill, Milwaukie, OR) was formulated, pelleted (Figure 1), and irradiated by TestDiet
(St. Louis, MO) and kept at 4 ̊C. Water for all groups was changed daily. The VSL#3
group was given the control chow diet with modification of water, formulated daily as
published previously [50]. Briefly, one pack of unflavored VSL#3 probiotic mixture was
dissolved in 1 L of water. Five-hundred milliliters was given to each of the two VSL#3
group cages. Water intake was monitored daily for all groups. Food intake was monitored periodically as described in Table 1. Body weight was measured on day 0, 8, and
14. Following 15 days of dietary intervention, mice were euthanized using CO2 followed
by tissue harvest. Blood was collected through cardiac puncture, processed to obtain
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serum with SST Microtainer tubes (Becton, Dickinson and Company, Franklin Lakes, NJ),
and stored at -80 ̊C (Figure 1). Animals were 5 weeks of age at the time of sacrifice.
Measurement of Fecal Bacteria
Fresh fecal samples were collected from the animals at specific times (Table 1).
Each mouse was placed into individual empty cages for a short period until defecation
and collection. Stools were stored at -80˚C. Microbial DNA was extracted from the feces
using the FastDNA spin kit for soil (MP Biomedicals, LLC, Solon, OH). DNA concentrations were quantified using a NanoDrop 2000 (Thermo Fisher Scientific Inc., Asherville,
NC) and diluted to 4 ng/µL before being stored at -20˚ C until analysis. Microbial profiles
were obtained using 96-well plates in a CFX96 Touch System (Bio-Rad Inc., Mississauga, ON). Samples were run in triplicates with a final volume of 10μL containing 5μL
of SsoAdvanced Universal SYBR Green Supermix, 0.5μM primers, and 4ng of template
DNA. Standard curves were generated using reference strains Escherichia coli (Total
bacteria), Bifidobacterium infantis (Bifidobacteria), and Lactobacillus rhamnosus (Lactobacillus) diluted 10-fold. The curves were normalized to copy number using previously
published 16S rRNA gene copy number values [51]. Group-specific primers are shown in
Table 2 along with reference strains for generating standard curves.
Amplicon Validation
Amplicon sizes of group specific primers for total bacteria, bifidobacteria, and lactobacillus were identified through ethidium bromide stained-agarose gel electrophoresis
after end-point polymerase chain reaction (PCR). Size was determined using a 100 base
pair ladder. F1 and F2 were female mouse samples on a control diet from another study
and used for comparison. C1, C2, and C5 were control mice. PS1, PS2, and PS5 were
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samples from mice given a 10% potato starch diet. V1, V2, and V5 were mice drinking
VSL#3 probiotic water. EC-ref, B-ref, and L-ref are DNA samples from our reference
strains: Escherichia coli, Bifidobacterium infantis, and Lactobacillus rhamnosus. VSL#3
was DNA extracted from the live bacteria found in the VSL#3 probiotic. NTC was the no
template control that only contained master mix, H2O, and primers.
LBP ELISA
Serum LBP levels were measured in duplicates with the Mouse Lipopolysaccharidebinding protein ELISA Kit (Aviva Systems Biology Corporation, San Diego, CA) read at
450 nm.
Glucose Assay
Serum glucose levels were measured in triplicates using a Glucose Colorimetric Assay Kit (Cayman Chemical, Ann Arbor, MI) read at 500nm.
Statistical Analysis
Statistical analyses were performed in SPSS version 24.0 (Armonk, NY) at a significance level of 0.05. Differences among the three groups were assessed using the
Kruskal-Wallis test and subsequent nonparametric Mann-Whitney U test.
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CHAPTER 4: RESULTS
Non-Invasive Labelling
The red label was easier to visualize and outlasted the blue as well as the green. The
green labelled mice required more reapplication of marker dye than the other two. Mice
did not show any differences in weight, food intake, or water intake because of the labelling.
Intake and Physiology
The mice showed normal food and water consumption after exposure to the diets
(Figure 3). There was an increase in water intake for the VSL#3 group. Food intake remained the same across all groups. Body weight at day 14 was statistically different between the potato starch group and the control only (Table 3). Tissue measurements in
the same table indicate an increase of large intestine weight in mice given the 10% potato starch supplementation. This is statistically different against the control and the
VSL#3 group. Blood glucose levels were almost identical in all the diet groups.
Fecal Microbial Profile
Quantitative PCR data showed similar numbers of total bacteria among the three
groups (Figure 4). Bifidobacteria levels were higher after potato starch supplementation
(9.25 ± 0.26) compared to control group as well as VSL#3 group (6.77 ± 0.60, 7.33 ±
0.21 respectively). VSL#3 supplementation was associated with more lactobacillus
(8.24 ± 0.21) compared to control and potato starch groups (7.71 ± 0.52, 7.73 ± 0.37 respectively). Values are given in log 16S rRNA gene copies/ng of total DNA (mean ± SD).
Differences among the three groups were assessed using the Kruskal-Wallis test and
subsequent nonparametric Mann-Whitney U test at a significance level of 0.05. Primers
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were validated through endpoint PCR and showed normal amplification (Figure 5). The
amplicon sizes matched those found in literature (Table 2).
LBP
Supplementation with VSL#3 was associated with lower LBP levels (Figure 6) with a
mean of 0.97 ± 0.38 µg/mL. LBP levels in potato starch (1.82 ± 0.60 µg/mL) have a
higher mean than controls (1.47 ± 0.45 µg/mL) but did not reach significance (p > 0.05)
using the Kruskal-Wallis test and subsequent nonparametric Mann-Whitney U test.
Samples were measured in duplicates (total n = 48). Values given as mean ± SD.
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CHAPTER 5: DISCUSSION
Many studies have shown the health benefits of incorporating probiotics and prebiotics in our diet. Few studies have looked at whether one is more beneficial than the
other. Both supplements have grown in demand and are commonly used to relieve gastrointestinal and digestive issues. Probiotics might appear more beneficial since they
contain actual living bacteria. These have been shown to help with diarrhea [52] and decrease the numbers of pathogenic bacteria in our gut [53]. They are also common in
foods like yogurt. The disadvantage is that viability and effectiveness of a probiotic can
depend on product brand, shelf life, bacterial count, temperature, pH, tissue adhesion,
and host immune response [54]. Many prebiotics, on the other hand, have longer shelf
lives and make it all the way to the colon without being absorbed. Therefore, instead of
introducing new bacteria, they can help increase the abundance of beneficial ones that
are already part of our GI tract. These would then produce SCFAs and help prevent colon
carcinogenesis [55]. Since prebiotics are dietary fiber they can be found in many affordable foods like fruits and vegetables. This makes them more accessible to the average
consumer.
In this study we compared the VSL#3 probiotic against the potato starch prebiotic invivo. We introduced mice to 15 days of potato starch or VSL#3 supplementation and
were surprised by the quick changes in their physiology and microbiome.
Both mice groups as well as controls consumed similar amounts of food. This was
an important observation since one group had customized food pellets that incorporated 10% potato starch. There was a concern that they would not like the food. Even
though this group showed normal food intake they were associated with increased body
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weight on day 14. This was an unexpected outcome since all groups had gained the
same amount of weight from day 0. The weight difference may have been due to slower
digestion since their large intestines were also heavier. We also know that potato starch
acts like fiber and increases colonic transit time. This slower digestion has not been associated with any detrimental outcomes. In fact, potato starch has been found to produce high levels of butyrate which has many health benefits [56]. One concern for the
mouse weight gain is that the potato starch may be selecting a gut microbiota that increases energy harvest [57]. However, this would likely involve higher levels of blood
glucose compared to the other groups. In our study we found that all groups had similar
blood glucose levels. The potato starch group did have a slight increase in LBP levels
which have been associated with obesity. Still, this increase was not statistically significant.
Our other test group had been given the VSL#3 probiotic supplement through a water mixture that was made fresh daily. Interestingly, this group was found to have consumed more liquid than the others. This may have been due to the small traces of cornstarch in VSL#3 that possibly improved the taste of the water. VSL#3 is a well established probiotic and there is extensive research demonstrating its benefits in ulcerative
colitis [39-41] and IBS [37, 38]. The VSL#3 product formula includes a mixture of both
lactobacillus and bifidobacteria species. However, when we looked at the mice fecal
microbial profiles we found that supplementation with VSL#3 only increased lactobacillus abundance. This differs slightly from another study that showed an increase in both
lactobacillus and bifidobacteria [58]. It is possible that 15 days of supplementation is
not enough time for bifidobacteria to become established. There may also be more lac-
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tobacillus in the original product, since the actual numbers for each probiotic species in
VSL#3 is not disclosed. Potato starch supplementation did a better job at increasing bifidobacteria abundance. This is supported by other studies [59, 60].
Lactobacillus and bifidobacteria are known to displace pathogens [61]. Therefore,
both bacterial groups can be beneficial. Studies have demonstrated that the combination of both bacterial groups may provide more benefits by suppressing the pro inflammatory cytokines IL-6 as well as IL-7 and promoting the expression of tight junction proteins claudin-1 and occluding, thus reinforcing the intestinal barrier [62]. It is possible
that a combination of potato starch and VSL#3 into a synbiotic might be the best way to
increase both lactobacillus and bifidobacteria. This has not yet been tested.
The VSL#3 probiotic was also associated with lower serum LBP levels, which is
consistent with the literature [63]. It was impressive to see how LBP levels dropped so
quickly after only 15 days of supplementation. Low LBP levels are associated with lower
risk of obesity [24] and inflammation [64].
Our results have validated some of the benefits of potato starch and VSL#3 that are
found in literature. While both products had short term effects on the microbiota, it is
difficult to say which is more favorable. VSL#3 seemed to trigger an increase in lactobacillus, while potato starch demonstrated an increase in lactobacillus. In the future, we
would like to see the effects of supplementation combining both VSL#3 and potato
starch as a synbiotic. This could provide better health effects since the inclusion of bifidobacteria and lactobacillus along with prebiotics have been found to enhance the survival and activity of a host in both in-vitro and in-vivo experiments [65]. Limitations of
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this study did not allow us to include female mice or a larger sample size for parametric
statistical analysis. This should also be incorporated in future research.
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CHAPTER 6: CONCLUSION
The VSL#3 probiotic and potato starch prebiotic are in high demand because of their
potential health benefits. In this study we used a non-invasive mouse model to observe
how the microbiota and murine physiology changed after just 15 days of supplementation. We found that the fecal bacteria can change significantly in only 15 days. There
was an increase in bifidobacteria after potato starch supplementation. This group also
showed higher body weight, although this may have been due to slower bowel movements. Mice given the VSL#3 probiotic were associated with greater lactobacillus
abundance. They also had lower levels of serum LBP which might suggest that they are
at lower risk for inflammation and obesity.
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TABLE 1. ANIMAL MODEL TIMELINE
DESCRIPTION

PROCEDURE

DATE

DAY -2

Acclimation Period

Tue, Aug 30, 2016

DAY -1

Acclimation Period

Wed, Aug 31, 2016

DAY 0

Experimental / Control Diet

DAY 1

Experimental / Control Diet

DAY 2

Experimental / Control Diet

DAY 3

Experimental / Control Diet

DAY 4

Experimental / Control Diet

DAY 5

Experimental / Control Diet

DAY 6

Experimental / Control Diet

DAY 7

Experimental / Control Diet

DAY 8

Experimental / Control Diet

DAY 9

Experimental / Control Diet

DAY 10

Experimental / Control Diet

DAY 11

Experimental / Control Diet

DAY 12

Experimental / Control Diet

DAY 13

Experimental / Control Diet

DAY 14

Experimental / Control Diet

fecal sample, food intake

Thu, Sep 15, 2016

DAY 15

Morning Fast (6 hours)

euthanasia, tissue harvest

Fri, Sep 16, 2016

fecal sample, start diet

Thu, Sep 1, 2016
Fri, Sep 2, 2016

food intake

Sat, Sep 3, 2016
Sun, Sep 4, 2016

fecal sample, food intake

Mon, Sep 5, 2016
Tue, Sep 6, 2016

food intake

Wed, Sep 7, 2016
Thu, Sep 8, 2016

fecal sample, food intake

Fri, Sep 9, 2016
Sat, Sep 10, 2016

food intake

Sun, Sep 11, 2016
Mon, Sep 12, 2016

food intake

Tue, Sep 13, 2016
Wed, Sep 14, 2016
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TABLE 2. PRIMERS FOR Q-PCR
MIC RO BIA L
GRO U P

Total Bacteria

Bifidobacteria

Lactobacillus

P R IMER S EQU ENC E,
5’-3’ (F O RWA RD, F A ND
REVERSE, R)

F: ACTCCTACGGGAGGCAG
R: CCGTMTTACCGCGGCTGCTGGCA

F: CGCGTCYGGTGTGAAAG
R: CCCCACATCCAGCATCCA

F: GCAGCAGTAGGGAATCTTCCA
R: GCATTYCACCGCTACACATG

GENO MIC
DN A
S T A ND A R D

A MP LIC O N
(BP )

REFERENC E

Escherichia coli

200

Amann, Krumholz, &
Stahl, 1990; W.T. Liu,
Mirzabekov, & Stahl,
2001

Bifidobacterium
infantis

242

Delroisse et al., 2008

Lactobacillus
rhamnosus

348

Castillo, et al., 2006
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TABLE 3. ANIMAL CHARACTERISTICS IN RESPONSE TO DIETARY INTAKE
control
(N=8)
Mean (SD)

potato starch
(N=8)
Mean (SD)

VSL#3
(N=8)
Mean (SD)

daily food intake per mouse (g)

3.63 (0.26)

3.70 (0.36)

3.74 (0.29)

daily water intake per mouse (mL)

5.54 (0.77)

5.55 (1.21)

6.65 (1.39)a

20.61 (0.94)a

21.84 (0.71)b

20.89 (1.05)a,b

total bodyweight gain from day 0 (g)

7.71 (0.94)

8.65 (0.71)

8.27 (1.33)

spleen weight (g)

0.08 (0.01)

0.08 (0.01)

0.07 (0.01)

spleen length (cm)

1.30 (0.2)

1.40 (0.1)

1.40 (0.1)

large intestine weight (g)

0.95 (0.08)

1.23 (0.10)a

0.95 (0.07)

large intestine length (cm)

10.10 (0.6)

10.70 (0.9)

10.50 (1.0)

105.57 (34.52)

113.81 (21.51)

116.05 (22.07)

DESCRIPTION

body weight at day 14 (g)

blood glucose (mg/dL)

*All tissues were collected on day 15. Values in the same row not sharing the same superscript are significantly different at p < .05 in the two-sided test of equality for column means. Tests assume equal variances and are adjusted
for all pairwise comparisons within a row using the Bonferroni correction.
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5L0D*

9GCZ
10% (w/w) potato starch
+ irradiation

FIGURE 1. CONTROL VS. FORMULATED DIETS
The 10% potato starch food pellets (TestDiet) were similar in color to the control (LabDiet). The cross-sectional shape
of the custom pellet was more circular rather than oval. The custom pellets were also smaller. Both were irradiated.
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BLUE

GREEN

RED

FIGURE 2. NON-INVASIVE ANIMAL LABELLING
Three out of four mice in every cage were labelled using permanent markers (Sharpie, Oak Brook, IL) at the base of
their tails in colors: red, green, and blue.
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FIGURE 3. INTAKE AND BODY WEIGHT OVER TIME
A. Mean daily food intake per mouse (g). Intake was measured periodically for each cage and was divided by the total
mice per cage (n=4).
B. Mean daily water intake per mouse (mL). Intake was measured per cage and divided by the total mice per cage
(n=4).
C. Mean mouse body weight (g).
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Relative abundance (log10)

Relative abundance (log10)

Total bacteria

Relative abundance (log10)

Lactobacillus

a

FIGURE 4. QUANTIFICATION OF FECAL BACTERIA
Abundance of microbial groups in fresh fecal samples measured by quantitative polymerase chain reaction (qPCR).
Values are given in log 16S rRNA gene copies/ng of total DNA. Values not sharing the same letter are significantly
different.

Lactobacillus

Bifidobacteria

Total bacteria
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FIGURE 5. PRIMER VALIDATION AND AMPLICON SIZE
F1 and F2 were female mouse samples on a control diet from another study and used for comparison. C1, C2, and C5
were control mice. PS1, PS2, and PS5 were samples from mice given a 10% potato starch diet. V1, V2, and V5 were
mice drinking VSL#3 probiotic water. EC-ref, B-ref, and L-ref were DNA samples from our reference strains: Escherichia coli, Bifidobacterium infantis, and Lactobacillus rhamnosus. VSL#3 was DNA extracted from the live bacteria
found in the VSL#3 probiotic. NTC was the no template control that only contained master mix, H2O, and primers.
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a

FIGURE 6. LEVELS OF SERUM LBP AFTER DIETARY SUPPLEMENTATION
Groups not sharing the same letter are significantly different.
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ABSTRACT
EXPLORING THE SHORT-TERM EFFECTS OF PROBIOTIC AND
PREBIOTIC SUPPLEMENTATION ON THE MICROBIOTA
AND PHYSIOLOGY OF MALE C57BL/6 MICE
by
MIGUEL A. RIVAS
December 2017
Advisor: Dr. Yifan Zhang
Major: Nutrition and Food Science
Degree: Master of Science
The gut microbiome may play a role in the development of chronic diseases like
obesity, diabetes, and heart disease. Diets including prebiotics or probiotics can alter
the abundance of gut bacterial groups and have subsequent health effects. In this study
we wanted to establish a method for comparing the benefits of commercial
supplements that alter the microbiota by monitoring fecal microbial profiles in male
C57BL/6 mice (n = 24) exposed to 15 days of dietary supplementation. A probiotic diet
(VSL#3) and a prebiotic diet (potato starch) were compared to a standard diet (n = 8 for
each group). Microbial profiles were obtained through qPCR using group-specific 16S
RNA primers.
The potato starch group showed higher body weight than the control (p < 0.05), but
was similar to the VSL#3 group. The large intestine weight of the potato starch group
was higher than the control and the potato starch group (p < 0.05). Food intake
remained the same across the groups. Daily water consumption was higher in the
VSL#3 group (6.65 ± 1.38 mL) as opposed to the potato starch and the control group
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(5.55 ± 1.21 mL, 5.54 ± 0.77 mL respectively). Blood glucose levels were similar
between all groups. Quantitative PCR data showed higher abundance of bifidobacteria
at a significant level compared to control and VSL#3 groups. VSL#3 supplementation
was associated with more lactobacillus (p < 0.05) and lower serum LBP levels (p < 0.05)
compared to control and potato starch groups.
The microbiota changes observed with VSL#3 and potato starch supplementation
were mostly consistent with the literature. However, VSL#3 probiotic did not
demonstrate the same increase in bifidobacteria as other studies. This may suggest a
need for prolonged consumption or combination with a prebiotic like potato starch.
Weight increase after potato starch supplementation might have been due to slower
digestion. There was a reduction in LBP levels after VSL#3 consumption, which may
help prevent inflammation and obesity.
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